Abstract:Dysregulation of the alternative splicing process results in aberrant mRNA transcripts, leading to dysfunctional proteins or nonsense-mediated decay that cause a wide range of mis-splicing diseases. Development of therapeutic strategies to target the alternative splicing process could potentially shift the mRNA splicing from disease isoforms to a normal isoform and restore functional protein. As a proof of concept, we focus on Stargardt disease (STGD1), an autosomal recessive inherited retinal disease caused by biallelic genetic variants in the gene. The splicing variants c.5461-10T>C and c.4773+3A>G in cause the skipping of exon 39-40 and exon 33-34 respectively. In this study, we compared the efficacy of different RNA-targeting systems to modulate these splicing defects, including four CRISPR-Cas13 systems (CASFx-1, CASFx-3, RBFOX1N-dCas13e-C and RBFOX1N-dPspCas13b-C) as well as an engineered U1 system (ExSpeU1). Using a minigene system containing variants in the human retinal pigment epithelium ARPE19, our results show that RBFOX1N-dPspCas13b-C is the best performing CRISPR-Cas system, which enabled up to 80% reduction of the mis-spliced c.5461-10T>C variants and up to 78% reduction of the c.4773+3A>G variants. In comparison, delivery of a single ExSpeU1 was able to effectively reduce the mis-spliced c.4773+3A>G variants by up to 84%. We observed that the effectiveness of CRISPR-based and U1 splicing regulation is strongly dependent on the sgRNA/snRNA targeting sequences, highlighting that optimal sgRNA/snRNA designing is crucial for efficient targeting of mis-spliced transcripts. Overall, our study demonstrated the potential of using RNA-targeting CRISPR-Cas technology and engineered U1 to reduce mis-spliced transcripts for , providing an important step to advance the development of gene therapy to treat STGD1.

CRISPR-dCas13d-based deep screening of proximal and distal splicing-regulatory elements

A CRISPR-dCas13 RNA-editing tool to study alternative splicing

“A CRISPR-dCas13 RNA-editing tool to study alternative splicing”

CRISPR-Mediated Enzyme Fragment Complementation Assay for Quantification of the Stability of Splice Isoforms

Specificity, synergy, and mechanisms of splice-modifying drugs

Repurposing CRISPR-Cas13 systems for robust mRNA trans-splicing

Rewriting endogenous human transcripts with -splicing

Systematic characterization of short intronic splicing-regulatory elements

Systematic characterization of short intronic splicing-regulatory elements in SMN2 pre-mRNA

CRISPR artificial splicing factors

Deep indel mutagenesis reveals the regulatory and modulatory architecture of alternative exon splicing

SpRY-mediated screens facilitate functional dissection of non-coding sequences at single-base resolution

One-Size-Fits-Many: Antisense oligonucleotides for rescuing splicing mutations in hotspot exons

ParSE-seq: a calibrated multiplexed assay to facilitate the clinical classification of putative splice-altering variants

Decoding RNA Metabolism by RNA-linked CRISPR Screening in Human Cells

Development and validation of AI/ML derived splice-switching oligonucleotides

Using RNA-targeting CRISPR-Cas13 and engineered U1 systems to reduce splice variants in Stargardt disease

A Molecular Chipper Technology For Crispr Sgrna Library Generation And Functional Mapping Of Noncoding Regions

SpliceTools, a Suite of Downstream RNA Splicing Analysis Tools to Investigate Mechanisms and Impact of Alternative Splicing

The cryo-EM structure of the SF3b spliceosome complex bound to a splicing modulator reveals a pre-mRNA substrate competitive mechanism of action.